Given that the target antigens CD33 and CD117 are expressed with intra- and inter-patient heterogeneity on primary human AML blasts, we next investigated the efficacy of Db-FM and AdFITC-CAR T-cells against AML patient blasts in vitro. This evidence concerns the gene KIT and acute myeloid leukemia.